Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)
Conditions: NSCLC; EGFR T790M; FDG-PET Intervention: Drug: Osimertinib Sponsor: Martin Schuler, Prof. Dr. med. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials